Inflazyme Pharmaceuticals Ltd. is a biopharmaceutical company developing novel small molecules for the treatment of inflammatory diseases, including treatments for asthma, allergies, and arthritis, and also has the rights to a patented small molecule with anti-tumor activity.
IZP's Institutional investors include Royal Bank, Royal Trust, Biotech Investments Ltd., Goldman Sachs, Business Development Bank of Canada, Sofinov, and Working Opportunity Fund.
Inflazyme currently has IZP-576 in Human Clinical Trials and expects to initiate Phase I Human Clinical Trials with three additional compounds before the end of 2000.
A recent financing and licensing agreement has infused in excess of $35,000,000 Canadian dollars into Inflazyme. The company continues to pursue collaboration opportunities, which should provide the company with additional funds.
For more information visit: inflazyme.com
An interview with CEO Ian McBeath: twst.com |
